Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1716362

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Artificial Intelligence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 May 2024 to Question 24269 on Lung Cancer: Artificial Intelligence, which (a) NHS trusts have and (b) imaging network has not received funding.
tabling member constituency	Hove
tabling member printed	Peter Kyle
uin	25291
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Since the initial announcements regarding funding for National Health Service trusts to integrate artificial intelligence into lung cancer imaging, adjustments have been made to the list of participants. Three trusts have withdrawn from the initiative, and five additional trusts have been onboarded, due to the inclusion of a new imaging network. As a result, as set out in the answer of 7 May 2024, there are now 66 trusts across 12 imaging networks that are participating in this initiative.</p><p>In the answer of 7 May 2024, 63 out of 66 trusts, in 11 of 12 imaging networks, had received funding. It is now confirmed that all 66 trusts in the 12 imaging networks participating have received or are in the process of receiving funding. These trusts are currently implementing artificial intelligence technologies to enhance diagnostic capabilities in lung cancer, consistent with the Government's commitment to advancing healthcare technology across the NHS.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:24:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4505 label Biography information for Peter Kyle

1716421

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions she (a) has had and (b) plans to have with (i) charities and (ii) other organisations working to secure UK access to new drugs for (A) incurable, (B) relapsing and (C) remitting cancers such as myeloma.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	25238
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Department ministers and officials regularly meet with a range of organisations, with an interest in securing patient access to new cancer medicines. The National Institute for Health and Care Excellence (NICE) is the body that develops authoritative, evidence-based guidance for the National Health Service on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits, including medicines for myeloma. The NICE aims to publish guidance on all new medicines close to the point of licensing wherever possible, and has recommended many cancer medicines for NHS use that are now available to NHS patients, including through the Cancer Drugs Fund.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:43:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1716422

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she (a) has had discussions and (b) plans to have discussions with the National Institute for Health and Care Excellence on (i) its use of the new severity modifier and (ii) how it (A) measures and (B) reports the impact of the modifier on approval of treatments for (1) cancers, (2) relapsing and remitting conditions and (3) conditions that are more prevalent in older people.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	25239
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Department regularly meets with colleagues in the National Institute for Health and Care Excellence (NICE) to discuss a range of issues, including in relation to the NICE’s methods for the evaluation of medicines. In 2022, the NICE introduced a number of changes to make its methods and processes fairer, faster, and more consistent. This includes the introduction of a broader severity modifier, in place of the end-of-life modifier. Since the changes were introduced, 79% of the NICE’s appraisals of cancer medicines carried out under the updated methods have recommended the use of the treatment for some or all of the eligible patient population, either for routine use or use through the Cancer Drugs Fund. The approval rate for all cancer appraisals carried out since 2009, when the end-of-life modifier was introduced, is 78%.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:48:27 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1716532

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Joint Replacements: Surgery
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of people received treatment for (a) knee and (b) hip replacements in surgical hubs in each of the last 12 months.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	25261
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>NHS England has introduced specific hub-level data site codes for all operational hubs in 2023, with 89% of the 101 operational hubs now reporting data against these codes. However, as many of the hubs have only recently introduced the data codes, NHS England have limited data available for the last 12 months, and much of this new data submission is still being validated. Therefore, NHS England currently do not have reliable, validated hub-specific data about specific procedures undertaken in hubs.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:52:57 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1716566

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liver Diseases: Shropshire
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure there are effective pathways for early detection of liver disease in Shropshire.
tabling member constituency	North Shropshire
tabling member printed	Helen Morgan
uin	25400
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>Early detection of liver disease is vital to enable interventions, and encourage behavioural changes that can potentially lead to recovery. Liver disease is one of the primary risk factors for liver cancer. Across the Shropshire, Telford, and Wrekin Integrated Care Board (ICB) area, the early detection of liver disease is led by primary care partners, and the ICB encourages general practitioners to follow best practice in the delivery of patient care pathways, to ensure the early detection of liver disease in patients. The Shrewsbury and Telford Hospital NHS Trust is working with primary care partners to increase awareness and provide tools to support this work. The hospital also carries out active outreach into the community for drug and alcohol patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 08:39:47 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4934 label Biography information for Helen Morgan

1716598

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Professions: Regulation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 June 2023 to Question 187004 on Health Professions: Regulation, if she will set out the timetable to remove the five year time limit for fitness to practice concerns to be investigated by the General Medical Council.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	25360
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>The Government is currently working with the General Medical Council (GMC) to develop a new legislative framework for the GMC, in relation to the regulation of doctors. As set out in the Government’s response to Regulating Healthcare Professionals, Protecting the Public, the Government has committed to the removal of any legislative restrictions on regulators from being able to consider fitness to practise concerns that are more than five years old. Regulators such as the GMC will have the discretion to determine whether a concern should be investigated based on the specific details of a fitness to practise case, which may include reflections on the length of time that has elapsed since the concern was raised or occurred. A public consultation on the new legislative framework will be taken forward in due course, and will adhere to the requirements of section 60 of the Health Act 1999.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/05/2024 10:27:27 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4769 label Biography information for Daisy Cooper

1715969

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy: Waiting Lists
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the proportion of cancer patients currently waiting more than 31 days for radiotherapy treatment.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL4423
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>According to the latest data, of those 10,328 cancer patients referred for first or subsequent treatment for radiotherapy in March 2024, 89.7% were treated within 31 days. The proportion of patients waiting more than 31 days for radiotherapy treatment in March 2024 was therefore 10.3%. This has decreased by 4.5% since January 2024.</p><p>We are aware of regional disparities in wait times for cancer treatment through NHS England’s data, and are considering the findings made by the Royal College of Radiologists. Tackling inequalities in outcomes, experience, and access of cancer diagnostics, including regional disparities, is a key focus of the Government. NHS England has commissioned six new cancer clinical audits in breast cancer, both primary and metastatic, as well as ovarian, pancreatic, non-Hodgkin lymphoma, and kidney cancer. These will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients. The first outcomes of these audits are expected in September 2024.</p><p>The Department is working closely with NHS England to make sure we have the right workforce with the right skills up and down the country. In 2023/24, NHS England invested an additional £50 million to increase the number of cancer and diagnostic specialists.</p><p>The Government is also backing the NHS Long Term Workforce Plan, with over £2.4 billion over the next five years to fund additional education and training places. The plan sets out an aim to double the number of medical school places in England to 15,000 places a year by 2031/32, and to work towards this expansion by increasing places by a third, to 10,000 a year, by 2028/29.</p><p>We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010. Regarding clinical oncology specifically, as of January 2024, there are currently over 1,600 FTE doctors working in the speciality of clinical oncology in National Health Service trusts and other core organisations in England. This is over 30, or 2.2%, more than last year, over 300, or 27.7%, more than 2019, and over 600, 66.5%, more than in 2010. This includes over 900 FTE consultants. This is over 40, or 5.1%, more than last year, over 100, 22.0%, more than in 2019, and over 400, 80.2%, more than in 2010.</p> answering member printed Lord Markham grouped question UIN HL4424 HL4425 question first answered 13/05/2024 11:23:46 answering member 4948 label Biography information for Lord Markham
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1715970

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: North East
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of findings from the Royal College of Radiologists, published in May, showing a regional disparity in wait times for cancer treatment in 2023, with 11 per cent of patients in England waiting more than 31 days for treatment after the decision to treat had been confirmed, compared to 19 per cent of patients in the North East and Yorkshire.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL4424
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>According to the latest data, of those 10,328 cancer patients referred for first or subsequent treatment for radiotherapy in March 2024, 89.7% were treated within 31 days. The proportion of patients waiting more than 31 days for radiotherapy treatment in March 2024 was therefore 10.3%. This has decreased by 4.5% since January 2024.</p><p>We are aware of regional disparities in wait times for cancer treatment through NHS England’s data, and are considering the findings made by the Royal College of Radiologists. Tackling inequalities in outcomes, experience, and access of cancer diagnostics, including regional disparities, is a key focus of the Government. NHS England has commissioned six new cancer clinical audits in breast cancer, both primary and metastatic, as well as ovarian, pancreatic, non-Hodgkin lymphoma, and kidney cancer. These will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients. The first outcomes of these audits are expected in September 2024.</p><p>The Department is working closely with NHS England to make sure we have the right workforce with the right skills up and down the country. In 2023/24, NHS England invested an additional £50 million to increase the number of cancer and diagnostic specialists.</p><p>The Government is also backing the NHS Long Term Workforce Plan, with over £2.4 billion over the next five years to fund additional education and training places. The plan sets out an aim to double the number of medical school places in England to 15,000 places a year by 2031/32, and to work towards this expansion by increasing places by a third, to 10,000 a year, by 2028/29.</p><p>We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010. Regarding clinical oncology specifically, as of January 2024, there are currently over 1,600 FTE doctors working in the speciality of clinical oncology in National Health Service trusts and other core organisations in England. This is over 30, or 2.2%, more than last year, over 300, or 27.7%, more than 2019, and over 600, 66.5%, more than in 2010. This includes over 900 FTE consultants. This is over 40, or 5.1%, more than last year, over 100, 22.0%, more than in 2019, and over 400, 80.2%, more than in 2010.</p> answering member printed Lord Markham grouped question UIN HL4423 HL4425 question first answered 13/05/2024 11:23:46 answering member 4948 label Biography information for Lord Markham
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1715971

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy: Staff
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to ensure that the 15 per cent shortfall in clinical oncologists, as estimated in the Royal College of Radiologists workforce census, does not impact the operational performance of radiotherapy services.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL4425
answer	answer is ministerial correction date of answer 13/05/2024 answer text <p>According to the latest data, of those 10,328 cancer patients referred for first or subsequent treatment for radiotherapy in March 2024, 89.7% were treated within 31 days. The proportion of patients waiting more than 31 days for radiotherapy treatment in March 2024 was therefore 10.3%. This has decreased by 4.5% since January 2024.</p><p>We are aware of regional disparities in wait times for cancer treatment through NHS England’s data, and are considering the findings made by the Royal College of Radiologists. Tackling inequalities in outcomes, experience, and access of cancer diagnostics, including regional disparities, is a key focus of the Government. NHS England has commissioned six new cancer clinical audits in breast cancer, both primary and metastatic, as well as ovarian, pancreatic, non-Hodgkin lymphoma, and kidney cancer. These will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatments and outcomes for patients. The first outcomes of these audits are expected in September 2024.</p><p>The Department is working closely with NHS England to make sure we have the right workforce with the right skills up and down the country. In 2023/24, NHS England invested an additional £50 million to increase the number of cancer and diagnostic specialists.</p><p>The Government is also backing the NHS Long Term Workforce Plan, with over £2.4 billion over the next five years to fund additional education and training places. The plan sets out an aim to double the number of medical school places in England to 15,000 places a year by 2031/32, and to work towards this expansion by increasing places by a third, to 10,000 a year, by 2028/29.</p><p>We are building our cancer workforce. In January 2024 there were over 35,200 full-time equivalent (FTE) staff in the cancer workforce, an increase of over 13,300, or 60.7% since January 2010. Regarding clinical oncology specifically, as of January 2024, there are currently over 1,600 FTE doctors working in the speciality of clinical oncology in National Health Service trusts and other core organisations in England. This is over 30, or 2.2%, more than last year, over 300, or 27.7%, more than 2019, and over 600, 66.5%, more than in 2010. This includes over 900 FTE consultants. This is over 40, or 5.1%, more than last year, over 100, 22.0%, more than in 2019, and over 400, 80.2%, more than in 2010.</p> answering member printed Lord Markham grouped question UIN HL4423 HL4424 question first answered 13/05/2024 11:23:46 answering member 4948 label Biography information for Lord Markham
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1715989

registered interest
date	07/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Injuries: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an estimate of when single-step scaffold insertion will be available on the NHS for people with torn cartilage injuries.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	24913
answer	answer is ministerial correction date of answer 10/05/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently consulting on draft interventional procedures guidance that recommends single-step scaffold insertion as an option for repairing symptomatic chondral knee defects, with standard arrangements in place for clinical governance, consent, and audit. The NICE currently expects to publish final guidance in September 2024. Once the NICE has published final guidance, National Health Service organisations will be expected to take it fully into account, but the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 10/05/2024 13:49:44 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4131 label Biography information for Jim Shannon